Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
108M
-
Number of holders
-
122
-
Total 13F shares, excl. options
-
63.6M
-
Shares change
-
+261K
-
Total reported value, excl. options
-
$1B
-
Value change
-
+$4.19M
-
Number of buys
-
63
-
Number of sells
-
-32
-
Price
-
$15.74
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock (ACRS) as of Q3 2022
132 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock as of Q3 2022.
Aclaris Therapeutics, Inc. - Common Stock (ACRS) has 122 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 63.6M shares
of 108M outstanding shares and own 58.68% of the company stock.
Largest 10 shareholders include BlackRock Inc. (4.81M shares), VR Adviser, LLC (4.56M shares), RA CAPITAL MANAGEMENT, L.P. (4.4M shares), BVF INC/IL (3.98M shares), Rock Springs Capital Management LP (3.96M shares), WELLINGTON MANAGEMENT GROUP LLP (3.45M shares), VANGUARD GROUP INC (2.93M shares), Foresite Capital Management IV, LLC (2.81M shares), ORBIMED ADVISORS LLC (2.76M shares), and COMMODORE CAPITAL LP (2.41M shares).
This table shows the top 122 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.